Advertisement


Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations

Pan Pacific Lymphoma Conference 2018

Advertisement

Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.



Related Videos

Lymphoma

Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.

Symptom Management
Immunotherapy

Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy

Susan Blumel, RN, BSN, of the University of Nebraska Medical Center, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, of Stanford Health Center, discuss immunotherapy, CAR T-cell toxicities, and the principles of team management.

Lymphoma

Jonathan W. Friedberg, MD, on Follicular Lymphoma: Novel Combination Therapies

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatments that enhance progression-free and overall survival and clear minimal residual disease—obinutuzumab plus chemotherapy, lenalidomide, and rituximab—and the types of lymphoma patients who may benefit.

CNS Cancers
Lymphoma

Philip J. Bierman, MD, on DLBCL: Managing Patients at Risk of CNS Involvement and Systemic Disease

Philip J. Bierman, MD, of the University of Nebraska Medical Center, discusses how to identify and treat the 1% to 2% of patients with diffuse large B-cell lymphoma who have central nervous system involvement as well as systemic sites at the time of diagnosis.

Lymphoma

Steven M. Horwitz, MD, on CD 30+ PTCL Subtypes: Treatment Update

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what could be the most effective treatments.

Advertisement

Advertisement




Advertisement